コンテンツへスキップ
Merck
  • Relationship between the severity of acne vulgaris and antimicrobial resistance of bacteria isolated from acne lesions in a hospital in Japan.

Relationship between the severity of acne vulgaris and antimicrobial resistance of bacteria isolated from acne lesions in a hospital in Japan.

Journal of medical microbiology (2014-02-14)
Keisuke Nakase, Hidemasa Nakaminami, Yuko Takenaka, Nobukazu Hayashi, Makoto Kawashima, Norihisa Noguchi
要旨

Propionibacterium acnes and Staphylococcus epidermidis are normal skin inhabitants that are frequently isolated from lesions caused by acne, and these micro-organisms are considered to contribute to the inflammation of acne. In the present study, we examined the antimicrobial susceptibilities and resistance mechanisms of P. acnes and S. epidermidis isolated from patients with acne vulgaris in a university hospital in Japan from 2009 to 2010. Additionally, we analysed the relationship between the antimicrobial resistance of P. acnes and the severity of acne vulgaris. Some P. acnes strains (18.8 %; 13/69) were resistant to clindamycin. All strains had a mutation in the 23S rRNA gene, except for one strain that expressed erm(X) encoding a 23S rRNA methylase. Tetracycline-resistant P. acnes strains were found to represent 4.3 % (3/69) of the strains, and this resistance was caused by a mutation in the 16S rRNA gene. Furthermore, three strains with reduced susceptibility to nadifloxacin (MIC = 16 µg ml(-1)) were detected. When analysing the correlation between the antimicrobial resistance of P. acnes and S. epidermidis, more than 80 % of the patients who carried clindamycin-resistant P. acnes also carried clindamycin-resistant S. epidermidis. However, no epidemic strain that exhibited antimicrobial resistance was detected in the P. acnes strains when analysed by PFGE. Therefore, our results suggest that the antimicrobial resistance of P. acnes is closely related to antimicrobial therapy. Additionally, those P. acnes strains tended to be frequently found in severe acne patients rather than in mild acne patients. Consequently, the data support a relationship between using antimicrobial agents and the emergence of antimicrobial resistance.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
クロラムフェニコール, ≥98% (HPLC)
Sigma-Aldrich
エリスロマイシン, BioReagent, suitable for cell culture
Sigma-Aldrich
レボフロキサシン, 98.0-102.0% anhydrous basis (HPLC)
Sigma-Aldrich
ミノサイクリン 塩酸塩, powder
Sigma-Aldrich
クロラムフェニコール, BioReagent, suitable for plant cell culture
Sigma-Aldrich
D-マンニトール, ≥98% (GC), suitable for plant cell culture
USP
マンニトール, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
D-マンニトール, ≥98% (GC)
Sigma-Aldrich
クラリトロマイシン, ≥95% (HPLC)
Sigma-Aldrich
D-マンニトール, BioUltra, ≥99.0% (sum of enantiomers, HPLC)
USP
Levofloxacin, United States Pharmacopeia (USP) Reference Standard
USP
シプロフロキサシン塩酸塩, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
クロラムフェニコール, meets USP testing specifications
Sigma-Aldrich
Erythromycin standard solution, 1 mg/mL in H2O
Sigma-Aldrich
クラリトロマイシン, 96.0-102.0% (HPLC)
USP
エリスロマイシン, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
D-マンニトール, ACS reagent
Supelco
シプロフロキサシン HCl, Pharmaceutical Secondary Standard; Certified Reference Material
USP
クラリトロマイシン, United States Pharmacopeia (USP) Reference Standard
Supelco
マンニトール, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D-マンニトール, SAJ special grade, ≥99.0%
USP
クラリトロマイシン, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
D-マンニトール, BioXtra, ≥98% (HPLC)
Sigma-Aldrich
D-マンニトール, meets EP, FCC, USP testing specifications
Sigma-Aldrich
エリスロマイシン, potency: ≥850 μg per mg
Supelco
クロラムフェニコール, VETRANAL®, analytical standard
Sigma-Aldrich
D-マンニトール, SAJ first grade, ≥99.0%
Supelco
クラリトロマイシン, Pharmaceutical Secondary Standard; Certified Reference Material
D-マンニトール, European Pharmacopoeia (EP) Reference Standard
Supelco
エリスロマイシン, Pharmaceutical Secondary Standard; Certified Reference Material